Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 8/20 | 0.53 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL347654 | 1.00 | P4HTM (0.53) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL8045282 | 0.98 | P4HTM (0.52) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL1550565 | 0.88 | EGLN1 (0.53) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL1550618 | 0.85 | EGLN1 (0.65) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL24812334 | 0.82 | EGLN1 (0.43) | KDM4EALDH1A1EGLN1L3MBTL1KMT2A | |
| SCHEMBL10638643 | 0.82 | EGLN1 (0.47) | KDM4EALDH1A1EGLN1L3MBTL1KMT2A | |
| SCHEMBL1061737 | 0.82 | ALDH1A1 (0.45) | KDM4EALDH1A1EGLN1L3MBTL1KMT2A | |
| SCHEMBL2468199 | 0.82 | KMT2A (0.49) | KDM4EALDH1A1EGLN1L3MBTL1KMT2A | |
| SCHEMBL18547170 | 0.82 | P4HTM (0.55) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL8238126 | 0.81 | PARP15 (0.51) | P4HTMP4HA1MIFKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 881 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117247372-A | Preparation method of oxindole compound | 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) | 2023-12-19 | — | — | CN | claimed |
| US-20190352312-A1 | PYRIDYL-TRIAZABICYCLES | HOFFMANN-LA ROCHE INC. | 2019-11-21 | — | — | US | claimed |
| US-10414780-B2 | Pyridyl-triazabicycles | HOFFMANN-LA ROCHE INC. (US) | 2019-09-17 | — | — | US | claimed |
| CN-104470915-B | Difluoro-hexahydro-cyclopentoxazines and difluoro-hexahydro-benzoxazines as BACE1 inhibitors | 霍夫曼-拉罗奇有限公司 | 2019-07-26 | — | — | CN | claimed |
| CN-106661053-B | Pyridyl-triazabicyclo compounds | 豪夫迈·罗氏有限公司 | 2019-07-12 | — | — | CN | claimed |
| EP-2855469-B1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | claimed |
| EP-3083644-B1 | 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES | HOFFMANN LA ROCHE (CH) | 2019-03-13 | — | — | EP | claimed |
| EP-3172206-B1 | PYRIDYL-TRIAZABICYCLES | HOFFMANN LA ROCHE (CH) | 2019-01-30 | — | — | EP | claimed |
| US-20180312528-A1 | PYRIDYL-TRIAZABICYCLES | HOFFMANN-LA ROCHE INC. | 2018-11-01 | — | — | US | claimed |
| US-20180194779-A1 | PYRIDYL-TRIAZABICYCLES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-07-12 | — | — | US | claimed |
| WO-2010128058-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | claimed |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| EP-0573581-A4 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1 INC (US) | 1994-06-29 | — | — | EP | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0573581-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, Inc. (US) | 1993-12-15 | — | — | EP | claimed |
| WO-1992014453-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352312-A1 | PYRIDYL-TRIAZABICYCLES | BACE1, BACE2, PSEN1 | P4HTM 1729/4885P4HA1 792/4885MIF 2324/4885 |
| US-20180194779-A1 | PYRIDYL-TRIAZABICYCLES | BACE1, BACE2, PSEN1 | P4HTM 1680/4885P4HA1 767/4885MIF 2474/4885 |
| US-10414780-B2 | Pyridyl-triazabicycles | BACE1, BACE2, PSEN1 | P4HTM 1729/4885P4HA1 792/4885MIF 2324/4885 |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | P4HTM 257/4885P4HA1 167/4885MIF 4264/4885 |
| US-20180312528-A1 | PYRIDYL-TRIAZABICYCLES | BACE1, BACE2, PSEN1 | P4HTM 1729/4885P4HA1 792/4885MIF 2324/4885 |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | P4HTM 296/4885P4HA1 258/4885MIF 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.